A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

  • STATUS
    Not Recruiting
  • End date
    Nov 25, 2023
  • participants needed
    382
  • sponsor
    Hoffmann-La Roche
Updated on 14 September 2022
combinations
measurable disease
metastasis
oxaliplatin
fluoropyrimidine
irinotecan
metastatic colorectal cancer
bevacizumab
adenocarcinoma
regorafenib

Summary

A phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with metastatic colorectal cancer (mCRC) that became refractory to first- and second-line standard therapies. Eligible patients will be assigned to one of several treatment arms.

Details
Condition Colorectal Cancer
Treatment Regorafenib, bevacizumab, Imprime PGG, Atezolizumab, Isatuximab, Idasanutlin, LOAd703, Selicrelumab, AB928
Clinical Study IdentifierNCT03555149
SponsorHoffmann-La Roche
Last Modified on14 September 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note